There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IN8bio (INAB – Research Report), Vigil Neuroscience Inc (VIGL – Research Report) and Outlook Therapeutics (OTLK – Research Report) with bullish sentiments.
IN8bio (INAB)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on IN8bio on November 26 and set a price target of $8.00. The company’s shares closed last Wednesday at $0.30, close to its 52-week low of $0.22.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of
Currently, the analyst consensus on IN8bio is a Moderate Buy with an average price target of $8.00, a 2480.6% upside from current levels. In a report issued on November 14, Mizuho Securities also maintained a Buy rating on the stock with a $2.00 price target.
See today’s best-performing stocks on TipRanks >>
Vigil Neuroscience Inc (VIGL)
In a report issued on November 26, Jason Butler from JMP Securities reiterated a Buy rating on Vigil Neuroscience Inc, with a price target of $22.00. The company’s shares closed last Wednesday at $2.30, close to its 52-week low of $2.08.
According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Vigil Neuroscience Inc is a Moderate Buy with an average price target of $14.80, which is a 563.7% upside from current levels. In a report issued on November 19, Mizuho Securities also maintained a Buy rating on the stock.
Outlook Therapeutics (OTLK)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Outlook Therapeutics yesterday and set a price target of $30.00. The company’s shares closed last Wednesday at $1.70, close to its 52-week low of $0.87.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Currently, the analyst consensus on Outlook Therapeutics is a Strong Buy with an average price target of $34.50.
Read More on INAB:
- IN8bio reports results from Phase 1 trial of INB-200
- IN8bio Advances Cancer Therapies Amid Financial Restructuring
- IN8bio price target lowered to $8 from $12.50 at H.C. Wainwright
- IN8bio files to sell 55.49M shares of common stock for holders
- IN8bio to sell 25.76M shares at 39.5c in private placement
